Investigating A Potential New Treatment For Stroke
Funder
National Health and Medical Research Council
Funding Amount
$878,522.00
Summary
Blood clots blocking blood flow to the brain (stroke) are a major cause of death and disability. Safety concerns limit approved therapies to a small subset of patients, highlighting an urgent need for safer, more effective drugs. Our studies show that inhibitors of the enzyme PI3Kbeta increase blood clot permeability, increasing clot ‘dissolvability’, without increased bleeding. This raises the possibility that PI3Kbeta inhibitors may represent a safe and effective adjuvant therapy for stroke.
Investigating The Mechanisms And Preventative Strategies To Alleviate The Burden Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
My research seeks to examine (i) the role of lifestyle, diet, physical activity, alcohol consumption and psychosocial factors, on risk factors for heart disease and stroke; (ii) elucidate the underlying mechanisms; and (iii) examine the developmental origins of heart disease and stroke within the Western Australian Pregnancy Cohort (Raine) Study, which is one of the largest longest running longitudinal pregnancy studies in the world.
Sphingosine Kinase As A Target For Anti-cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$590,785.00
Summary
Sphingosine kinase is a protein involved in the development and progression of numerous types of solid tumors and leukaemias. We have recently made a major break-through by identifing how the cancer-inducing activity of sphingosine kinase is controlled. In this study we will target these control mechanisms to develop potential new anti-cancer therapies.
Manipulating Oncogenic-signalling Pathways In The Genesis And Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$601,484.00
Summary
Melanoma is a major Australian health problem. It is the third most common cancer in men and women and has a disproportionately heavy impact on productive years of life. The use of small molecule inhibitors is the most promising strategy for treating melanoma. In this project, we will examine the mechanisms of resistance to this class of drugs and define new drug targets by examining the molecular-circuitry is damaged in melanomas. This work will greatly accelerate the development of new therapi ....Melanoma is a major Australian health problem. It is the third most common cancer in men and women and has a disproportionately heavy impact on productive years of life. The use of small molecule inhibitors is the most promising strategy for treating melanoma. In this project, we will examine the mechanisms of resistance to this class of drugs and define new drug targets by examining the molecular-circuitry is damaged in melanomas. This work will greatly accelerate the development of new therapies.Read moreRead less
I lead a research program to improve outcomes for patients with chronic myeloid leukaemia (CML). We aim to identify poor risk patients and test new treatment strategies to reduce adverse outcomes. In good risk patients we aim to reduce the need for lifelong drug dependency. Through a combination of clinical trials, innovative correlative studies, and strong scientific collaborations, my team will continue to improve outcomes for CML patients globally.
The key goal of my research is to understand the role of protein phosphorylation in controlling metabolism, with a special emphasis on the structure and function of members of the AMP-activated protein kinase (AMPK) pathway. This is important because the function and survival of all organisms is dependent on the dynamic control of energy metabolism, with energy demand matched to energy supply.
Developing New Therapeutic Strategies For Brain Cancer
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
Each year, over 1,500 Australians will develop brain cancer. Unlike many cancers, it cannot be prevented by lifestyle changes. Adults with brain cancer usually die within 2 years. The overall aims of this funding are to extend patients' lives and build brain cancer research in Australia so that we have the best chance of curing this disease. The expected outcome is clinical trial of drug candidates for the most common and most deadly brain cancer, high-grade glioma.
Translational Research Initiatives In Acute Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Recent research has focussed on molecular characterisation of high-risk acute leukaemia subtypes. This proposal will combine the power of genomic analysis, global analysis of protein kinases and stringent preclinical drug testing in order to improve the treatment of these high-risk acute leukaemia subtypes. Several innovative and interrelated projects within this Program will utilise a unique and clinically relevant experimental model to achieve their goals.
While most leukemia patients initially respond well to chemotherapy, >70% die because the disease returns as a result of the survival of leukaemia cells following treatment. We seek to block the switch mechanisms within leukemic cells that allow them to survive current drug therapies. We now seek to examine the therapeutic potential of our discovery with a view toward developing new targetted therapies in the future.
Manipulating Oncogene Addiction And Immunity In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$687,975.00
Summary
Melanoma is a major Australian health problem and a common cause of cancer death in young adults. Treatment of melanoma has been revolutionised in the last few years, but many patients fail to respond to new therapies or rapidly progress on treatment. This proposal examines the mechanisms that drive resistance to therapy and identifies markers predictive of clinical response. This approach will accelerate the development of new strategies and improve patient care by personalising treatment.